SynthesisBMC cardiovascular disorders2026
Clinical outcomes observed with Rivaroxaban versus low molecular weight heparin (Enoxaparin) for thrombo-prophylaxis following total knee arthroplasty: a meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn this analysis, we aimed to systematically compare the clinical outcomes observed with rivaroxaban versus low molecular weight heparin (LMWH) [enoxaparin] for thrombo-prophylaxis following total knee arthroplasty (TKA).
methodsRelevant studies based on rivaroxaban versus LMWH for thrombo-prophylaxis following TKA were searched through online databases. Data sources were MEDLINE, EMBASE, Cochrane database, Google scholar, www. CLINICALTRIALS: gov and Web of Science. Nine studies with a total number of 26,675 participants were included. Clinical outcomes (adverse efficacy and bleeding outcomes) were considered as the endpoints in this analysis. The Revman software was used for data analysis. Risk ratios (RR) with 95% confidence intervals (CI) were used to represent the results.
resultsA total number of 26,675 participants were included in this analysis whereby 13,496 participants were assigned to rivaroxaban and 13,179 participants were assigned to LMWH. Our current results showed that deep venous thrombosis (RR: 0.60, 95% CI: 0.51 - 0.71; P = 0.00001), venous thromboembolism (RR: 0.56, 95% CI: 0.45 - 0.70; P = 0.00001), and all-cause mortality (RR: 0.54, 95% CI: 0.33 - 0.87; P = 0.01) were significantly lower with rivaroxaban compared to LMWH for thrombo-prophylaxis after TKA. Adverse cardiac events (RR: 1.50, 95% CI: 0.53 - 4.21; P = 0.44) were similarly manifested. However, any bleeding event (RR: 1.18, 95% CI: 1.07 - 1.31; P = 0.001), major bleeding (RR: 1.54, 95% CI: 1.12 - 2.11; P = 0.008), non-major bleeding (RR: 1.15, 95% CI: 1.01 - 1.30; P = 0.03), minor bleeding (RR: 1.19, 95% CI: 1.06 - 1.32; P = 0.002) and bleeding leading to re-operation (RR: 1.62, 95% CI: 1.08 - 2.44; P = 0.02) were significantly higher with rivaroxaban when compared to LMWH.
conclusionOur analysis showed that rivaroxaban when used as thrombo-prophylaxis following TKA, significantly reduced thrombotic outcomes when compared to LMWH. However, the risks of bleeding events including major and minor bleeding events were significantly increased in comparison to LMWH. Therefore, further larger studies should be able to confirm our hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.